Yahoo · Oct 31, 2026
EBay Leads Five Stocks Near Buy Points From Resilient Sectors
Ebay, Quest Diagnostics, Fastenal, Chubb trade in or around buy points after earnings. TG Therapeutics breaks out.
TG
NASDAQ · TGTX
TG Therapeutics, Inc.
Healthcare · Biotechnology
$61.18
Down-$1.23 (-2.01%)
Updated Nov 3, 2026, 1:54 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- 77.67
- Dividend yield
- 0.00%
- 52-week range
- $26.76 – $61.76
- Volume
- 2.86M
- Avg. volume
- 1.87M
Price performance · TGTX
TGTX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
TGTX closed at $61.18 after 20 trading sessions, up 13.49% for the selected period.
- Last close
- $61.18
- Period change
- +13.49%
- Period low
- $52.19
- Period high
- $61.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $58.15 | $61.7599 | $58.00 | $61.18 | 2.86M |
| Oct 29, 2026 | $57.81 | $58.96 | $56.93 | $58.08 | 1.79M |
| Oct 28, 2026 | $55.84 | $57.46 | $55.66 | $57.40 | 933.76K |
| Oct 27, 2026 | $54.10 | $57.08 | $53.88 | $56.44 | 1.48M |
| Oct 26, 2026 | $54.81 | $55.49 | $53.71 | $54.79 | 1.19M |
| Oct 23, 2026 | $52.56 | $55.805 | $51.8327 | $54.17 | 1.98M |
| Oct 22, 2026 | $53.02 | $53.70 | $52.53 | $53.16 | 1.29M |
| Oct 21, 2026 | $54.51 | $54.9465 | $52.73 | $53.20 | 1.18M |
| Oct 20, 2026 | $53.36 | $55.32 | $53.08 | $54.53 | 1.06M |
| Oct 19, 2026 | $54.35 | $54.97 | $52.90 | $53.30 | 1.55M |
| Oct 16, 2026 | $56.00 | $56.245 | $53.66 | $53.97 | 1.77M |
| Oct 15, 2026 | $55.12 | $56.83 | $54.755 | $56.00 | 1.81M |
| Oct 14, 2026 | $54.08 | $55.37 | $53.36 | $54.37 | 1.29M |
| Oct 13, 2026 | $55.23 | $55.39 | $53.63 | $54.34 | 1M |
| Oct 12, 2026 | $55.38 | $55.86 | $54.65 | $55.27 | 758.15K |
| Oct 9, 2026 | $53.72 | $55.46 | $53.36 | $55.37 | 1.62M |
| Oct 8, 2026 | $53.34 | $53.90 | $52.1201 | $53.34 | 1.74M |
| Oct 7, 2026 | $51.83 | $53.88 | $51.405 | $52.95 | 1.51M |
| Oct 6, 2026 | $54.11 | $54.11 | $51.34 | $52.19 | 2.41M |
| Oct 5, 2026 | $54.35 | $54.75 | $53.321 | $53.91 | 1.55M |
Latest TGTX news
The latest Smart Investors Daily articles mentioning TGTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TGTX research
Overview
Company profile and research snapshot.
Company profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $60.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 27, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 7, 2026 | B of A Securities | Underperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
TG Therapeutics Is Up 98%, But The Story Isn't Finished
One concrete shift for TG Therapeutics this year was the push to simplify and broaden BRIUMVI use, from single 600 mg Day 1 infusions in relapsing multiple sclerosis to new trials in conditions like myasthenia gravis and treatment-resistant schizophrenia. Investors who held TG Therapeutics from the start of the year are up 98.4%, including dividends. If you were deciding on 1 January, what needed to be true about that lone franchise and margin path to make such a decision feel sensible? TG...
Yahoo · Oct 30, 2026
TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz
Investors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2.
Yahoo · Oct 30, 2026
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
